Depomed Inc. (DEPO) Set to Announce Earnings on Wednesday

Depomed Inc. (NASDAQ:DEPO) is scheduled to release its earnings data after the market closes on Wednesday, July 27th. Analysts expect Depomed to post earnings of $0.26 per share for the quarter.

Depomed (NASDAQ:DEPO) last issued its quarterly earnings results on Thursday, May 5th. The specialty pharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by $0.05. During the same period in the previous year, the business posted ($0.13) EPS. The company had revenue of $104.60 million for the quarter, compared to analyst estimates of $106.88 million. The company’s revenue was up 230.0% on a year-over-year basis. On average, analysts expect Depomed to post $1.20 EPS for the current fiscal year and $1.60 EPS for the next fiscal year.

In other Depomed news, CFO August J. Moretti sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $18.00, for a total transaction of $90,000.00. Following the transaction, the chief financial officer now owns 22,879 shares in the company, valued at $411,822. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Thadd M. Vargas sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $17.64, for a total value of $264,600.00. Following the transaction, the vice president now owns 124,297 shares in the company, valued at approximately $2,192,599.08. The disclosure for this sale can be found here.

DEPO has been the subject of a number of research reports. Cantor Fitzgerald restated a “buy” rating and issued a $26.00 target price on shares of Depomed in a research note on Tuesday, March 29th. Roth Capital restated a “buy” rating on shares of Depomed in a research note on Monday, March 28th. Leerink Swann restated an “outperform” rating on shares of Depomed in a research note on Tuesday, March 29th. Mizuho reiterated a “neutral” rating and issued a $18.00 price target (up previously from $14.00) on shares of Depomed in a report on Saturday, April 9th. Finally, Vetr cut Depomed from a “strong-buy” rating to a “buy” rating and set a $18.81 price target on the stock. in a report on Monday, April 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $22.89.

Shares of Depomed Inc. (NASDAQ:DEPO) traded up 0.16% during mid-day trading on Tuesday, hitting $19.07. 503,937 shares of the company were exchanged. The stock’s market cap is $1.17 billion. Depomed Inc. has a 12-month low of $12.25 and a 12-month high of $33.17. The stock’s 50-day moving average price is $19.44 and its 200 day moving average price is $17.13.